GLENMARK PHARMA | LAURUS LABS | GLENMARK PHARMA/ LAURUS LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -34.6 | 143.3 | - | View Chart |
P/BV | x | 3.1 | 6.0 | 52.5% | View Chart |
Dividend Yield | % | 0.2 | 0.4 | 53.0% |
GLENMARK PHARMA LAURUS LABS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
GLENMARK PHARMA Mar-23 |
LAURUS LABS Mar-23 |
GLENMARK PHARMA/ LAURUS LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 487 | 626 | 77.8% | |
Low | Rs | 349 | 287 | 121.7% | |
Sales per share (Unadj.) | Rs | 460.4 | 112.1 | 410.5% | |
Earnings per share (Unadj.) | Rs | 13.4 | 14.8 | 90.4% | |
Cash flow per share (Unadj.) | Rs | 35.0 | 20.8 | 168.4% | |
Dividends per share (Unadj.) | Rs | 2.50 | 2.00 | 125.0% | |
Avg Dividend yield | % | 0.6 | 0.4 | 136.5% | |
Book value per share (Unadj.) | Rs | 335.1 | 74.7 | 448.4% | |
Shares outstanding (eoy) | m | 282.17 | 538.65 | 52.4% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.9 | 4.1 | 22.3% | |
Avg P/E ratio | x | 31.3 | 30.9 | 101.3% | |
P/CF ratio (eoy) | x | 11.9 | 21.9 | 54.4% | |
Price / Book Value ratio | x | 1.2 | 6.1 | 20.4% | |
Dividend payout | % | 18.7 | 13.5 | 138.2% | |
Avg Mkt Cap | Rs m | 117,953 | 245,840 | 48.0% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 27,810 | 5,574 | 498.9% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 129,901 | 60,406 | 215.0% | |
Other income | Rs m | 3,168 | 60 | 5,279.8% | |
Total revenues | Rs m | 133,069 | 60,466 | 220.1% | |
Gross profit | Rs m | 15,125 | 15,922 | 95.0% | |
Depreciation | Rs m | 6,113 | 3,241 | 188.6% | |
Interest | Rs m | 3,496 | 1,652 | 211.7% | |
Profit before tax | Rs m | 8,685 | 11,089 | 78.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 4,911 | 3,123 | 157.2% | |
Profit after tax | Rs m | 3,774 | 7,966 | 47.4% | |
Gross profit margin | % | 11.6 | 26.4 | 44.2% | |
Effective tax rate | % | 56.5 | 28.2 | 200.8% | |
Net profit margin | % | 2.9 | 13.2 | 22.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 98,737 | 34,617 | 285.2% | |
Current liabilities | Rs m | 50,455 | 24,323 | 207.4% | |
Net working cap to sales | % | 37.2 | 17.0 | 218.1% | |
Current ratio | x | 2.0 | 1.4 | 137.5% | |
Inventory Days | Days | 7 | 14 | 46.3% | |
Debtors Days | Days | 115 | 10 | 1,205.9% | |
Net fixed assets | Rs m | 76,920 | 41,987 | 183.2% | |
Share capital | Rs m | 282 | 1,077 | 26.2% | |
"Free" reserves | Rs m | 94,281 | 39,177 | 240.7% | |
Net worth | Rs m | 94,563 | 40,255 | 234.9% | |
Long term debt | Rs m | 38,521 | 7,614 | 505.9% | |
Total assets | Rs m | 175,658 | 76,604 | 229.3% | |
Interest coverage | x | 3.5 | 7.7 | 45.2% | |
Debt to equity ratio | x | 0.4 | 0.2 | 215.4% | |
Sales to assets ratio | x | 0.7 | 0.8 | 93.8% | |
Return on assets | % | 4.1 | 12.6 | 33.0% | |
Return on equity | % | 4.0 | 19.8 | 20.2% | |
Return on capital | % | 9.2 | 26.6 | 34.4% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 22.7 | 0.0% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | 13,720 | 0.0% | |
Fx inflow | Rs m | 46,464 | 43,470 | 106.9% | |
Fx outflow | Rs m | 12,712 | 13,720 | 92.7% | |
Net fx | Rs m | 33,751 | 29,750 | 113.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 6,254 | 9,939 | 62.9% | |
From Investments | Rs m | -5,285 | -9,961 | 53.1% | |
From Financial Activity | Rs m | -775 | -266 | 290.8% | |
Net Cashflow | Rs m | 325 | -297 | -109.5% |
Indian Promoters | % | 46.6 | 27.2 | 171.5% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 34.8 | 37.8 | 92.1% | |
FIIs | % | 21.4 | 26.0 | 82.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 53.4 | 72.8 | 73.3% | |
Shareholders | 199,451 | 356,830 | 55.9% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare GLENMARK PHARMA With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Glenmark Pharma | LAURUS LABS | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.61% | -0.53% | 0.15% |
1-Month | 6.08% | 1.73% | 0.33% |
1-Year | 94.86% | 39.30% | 54.36% |
3-Year CAGR | 22.20% | -2.11% | 14.52% |
5-Year CAGR | 10.77% | 41.10% | 20.24% |
* Compound Annual Growth Rate
Here are more details on the Glenmark Pharma share price and the LAURUS LABS share price.
Moving on to shareholding structures...
The promoters of Glenmark Pharma hold a 46.6% stake in the company. In case of LAURUS LABS the stake stands at 27.2%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Glenmark Pharma and the shareholding pattern of LAURUS LABS .
Finally, a word on dividends...
In the most recent financial year, Glenmark Pharma paid a dividend of Rs 2.5 per share. This amounted to a Dividend Payout ratio of 18.7%.
LAURUS LABS paid Rs 2.0, and its dividend payout ratio stood at 13.5%.
You may visit here to review the dividend history of Glenmark Pharma, and the dividend history of LAURUS LABS .
For a sector overview, read our pharmaceuticals sector report.
After opening the negative note, Indian share markets Slipped further as the session progressed and ended the day weak.